Guardian Pharmacy (GRDN) Fundamental Analysis: Revenue, Earnings & Valuation

6.06 / 10

Outperform

Fundamentally, GRDN is rated Outperform with a 6.06 score. Strong drivers include total profit YoY growth (210%) and operating cash‑flow growth (73%). Revenue‑to‑market value is positive, yet asset‑to‑market and cash‑to‑market ratios lag, tempering the view.

Analysis Checks(4/10)

Revenue-MV

Value0.48

Score3/3

Weight55.64%

1M Return7.98%

Net cash flow from operating activities per share (YoY growth rate %)

Value72.88

Score2/3

Weight13.75%

1M Return2.28%

PB-ROE

Value3.55

Score0/3

Weight-6.01%

1M Return-1.30%

Basic earnings per share (YoY growth rate %)

Value144.63

Score1/3

Weight3.84%

1M Return0.59%

Total profit (YoY growth rate %)

Value210.45

Score2/3

Weight11.85%

1M Return1.87%

Net cash flow from operating activities (YoY growth rate %)

Value72.97

Score2/3

Weight9.77%

1M Return1.55%

Cash-UP

Value-0.10

Score1/3

Weight4.00%

1M Return0.66%

Diluted earnings per share (YoY growth rate %)

Value144.07

Score1/3

Weight4.18%

1M Return0.65%

Asset-MV

Value-0.55

Score0/3

Weight-5.29%

1M Return-0.96%

Cash-MV

Value-0.51

Score1/3

Weight8.27%

1M Return1.42%

Is GRDN fundamentally strong?

GRDN scores 6.06/10 on fundamentals and holds a Discounted valuation at present. Backed by its 26.76% ROE, 3.38% net margin, 49.46 P/E ratio, 11.17 P/B ratio, and 0.00% earnings growth, these metrics solidify its Outperform investment rating.